HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rodan + Fields Prostaglandin Lash Boost Suit Appears Headed For Settlement

Executive Summary

The San Francisco-based multi-level beauty marketer seems intent on putting an end to a multi-year, consolidated putative class action in California federal court alleging it failed to disclose risks associated with the prostaglandin analog in its Lash Boost conditioning serum.

You may also be interested in...



EU Commission Wants Expert Opinion On Prostaglandin Analogs In Eyelash Growth Cosmetics

The Scientific Committee on Consumer Safety will consider available safety data for prostaglandin analogs isopropyl cloprostenate, ethyl tafluprostamide and others with known use in eyelash-growth cosmetic products in the EU. Currently, the substances are not restricted in cosmetic products.

Rodan + Fields Concealed Prostaglandin Risks From Lash Boost Users – Class Action

Marketers of cosmetic lash enhancers that haven’t abandoned prostaglandin analogs in favor of peptides or botanical extracts should take heed of a proposed class action against Rodan + Fields in California’s Northern District. Plaintiffs say they would not have purchased the firm’s Lash Boost and suffered alleged adverse effects if they’d been properly informed about product risks.

Allergan Continues Legal Sparring With Cosmetic Eyelash-Growth Brands

Latisse marketer Allergan continues to lock horns with cosmetic firms offering non-FDA-approved, prostaglandin-based eyelash-enhancement products, pursuing injunction and damages in California court.

Related Content

Topics

UsernamePublicRestriction

Register

RS151545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel